nodes	percent_of_prediction	percent_of_DWPC	metapath
Pralatrexate—TYMS—Capecitabine—kidney cancer	0.409	0.591	CbGbCtD
Pralatrexate—TYMS—Gemcitabine—kidney cancer	0.283	0.409	CbGbCtD
Pralatrexate—SLC19A1—gonad—kidney cancer	0.00452	0.152	CbGeAlD
Pralatrexate—FPGS—cortex of kidney—kidney cancer	0.00316	0.106	CbGeAlD
Pralatrexate—FPGS—cardiac atrium—kidney cancer	0.00301	0.101	CbGeAlD
Pralatrexate—TYMS—nephron tubule—kidney cancer	0.00242	0.0813	CbGeAlD
Pralatrexate—DHFR—nephron tubule—kidney cancer	0.0024	0.0805	CbGeAlD
Pralatrexate—FPGS—Everolimus—Temsirolimus—kidney cancer	0.00227	0.355	CbGdCrCtD
Pralatrexate—DHFR—renal system—kidney cancer	0.00218	0.0731	CbGeAlD
Pralatrexate—DHFR—kidney—kidney cancer	0.00211	0.0707	CbGeAlD
Pralatrexate—TYMS—cortex of kidney—kidney cancer	0.00207	0.0696	CbGeAlD
Pralatrexate—DHFR—cortex of kidney—kidney cancer	0.00205	0.0689	CbGeAlD
Pralatrexate—TYMS—gonad—kidney cancer	0.00197	0.0662	CbGeAlD
Pralatrexate—DHFR—gonad—kidney cancer	0.00196	0.0656	CbGeAlD
Pralatrexate—DHFR—cardiac atrium—kidney cancer	0.00195	0.0655	CbGeAlD
Pralatrexate—TYMS—Docetaxel—Paclitaxel—kidney cancer	0.00111	0.174	CbGdCrCtD
Pralatrexate—TYMS—Sirolimus—Everolimus—kidney cancer	0.000533	0.0836	CbGdCrCtD
Pralatrexate—TYMS—Sirolimus—Temsirolimus—kidney cancer	0.000533	0.0836	CbGdCrCtD
Pralatrexate—TYMS—Gefitinib—Erlotinib—kidney cancer	0.000531	0.0833	CbGdCrCtD
Pralatrexate—Abdominal pain—Temsirolimus—kidney cancer	0.00053	0.00288	CcSEcCtD
Pralatrexate—Body temperature increased—Temsirolimus—kidney cancer	0.00053	0.00288	CcSEcCtD
Pralatrexate—Dehydration—Paclitaxel—kidney cancer	0.00053	0.00288	CcSEcCtD
Pralatrexate—Liver function test abnormal—Paclitaxel—kidney cancer	0.000526	0.00286	CcSEcCtD
Pralatrexate—Hypokalaemia—Paclitaxel—kidney cancer	0.000519	0.00282	CcSEcCtD
Pralatrexate—Gastrointestinal pain—Pazopanib—kidney cancer	0.000517	0.00281	CcSEcCtD
Pralatrexate—Cough—Erlotinib—kidney cancer	0.000515	0.0028	CcSEcCtD
Pralatrexate—Toxic epidermal necrolysis—Paclitaxel—kidney cancer	0.000513	0.00279	CcSEcCtD
Pralatrexate—Abdominal pain—Pazopanib—kidney cancer	0.0005	0.00272	CcSEcCtD
Pralatrexate—Oedema—Everolimus—kidney cancer	0.000499	0.00271	CcSEcCtD
Pralatrexate—Back pain—Sunitinib—kidney cancer	0.000494	0.00269	CcSEcCtD
Pralatrexate—Anaemia—Sorafenib—kidney cancer	0.000491	0.00267	CcSEcCtD
Pralatrexate—Thrombocytopenia—Vinblastine—kidney cancer	0.000491	0.00267	CcSEcCtD
Pralatrexate—Thrombocytopenia—Everolimus—kidney cancer	0.000489	0.00266	CcSEcCtD
Pralatrexate—Tachycardia—Everolimus—kidney cancer	0.000487	0.00265	CcSEcCtD
Pralatrexate—Neoplasm malignant—Doxorubicin—kidney cancer	0.000486	0.00264	CcSEcCtD
Pralatrexate—Oedema—Erlotinib—kidney cancer	0.000482	0.00262	CcSEcCtD
Pralatrexate—Asthenia—Temsirolimus—kidney cancer	0.000481	0.00262	CcSEcCtD
Pralatrexate—Anorexia—Vinblastine—kidney cancer	0.000478	0.0026	CcSEcCtD
Pralatrexate—Anorexia—Everolimus—kidney cancer	0.000476	0.00259	CcSEcCtD
Pralatrexate—Leukopenia—Sorafenib—kidney cancer	0.000475	0.00258	CcSEcCtD
Pralatrexate—Pruritus—Temsirolimus—kidney cancer	0.000475	0.00258	CcSEcCtD
Pralatrexate—Anaemia—Sunitinib—kidney cancer	0.000472	0.00257	CcSEcCtD
Pralatrexate—Thrombocytopenia—Erlotinib—kidney cancer	0.000472	0.00256	CcSEcCtD
Pralatrexate—Pancytopenia—Paclitaxel—kidney cancer	0.000468	0.00254	CcSEcCtD
Pralatrexate—Pain in extremity—Capecitabine—kidney cancer	0.000468	0.00254	CcSEcCtD
Pralatrexate—Cough—Sorafenib—kidney cancer	0.000463	0.00252	CcSEcCtD
Pralatrexate—Neutropenia—Paclitaxel—kidney cancer	0.000461	0.0025	CcSEcCtD
Pralatrexate—Diarrhoea—Temsirolimus—kidney cancer	0.000459	0.0025	CcSEcCtD
Pralatrexate—Anorexia—Erlotinib—kidney cancer	0.000459	0.0025	CcSEcCtD
Pralatrexate—Upper respiratory tract infection—Paclitaxel—kidney cancer	0.000458	0.00249	CcSEcCtD
Pralatrexate—Leukopenia—Sunitinib—kidney cancer	0.000457	0.00249	CcSEcCtD
Pralatrexate—Asthenia—Pazopanib—kidney cancer	0.000454	0.00247	CcSEcCtD
Pralatrexate—Pruritus—Pazopanib—kidney cancer	0.000447	0.00243	CcSEcCtD
Pralatrexate—Anaemia—Dactinomycin—kidney cancer	0.000447	0.00243	CcSEcCtD
Pralatrexate—Cough—Sunitinib—kidney cancer	0.000446	0.00242	CcSEcCtD
Pralatrexate—Dyspnoea—Everolimus—kidney cancer	0.000445	0.00242	CcSEcCtD
Pralatrexate—Decreased appetite—Vinblastine—kidney cancer	0.000436	0.00237	CcSEcCtD
Pralatrexate—Dehydration—Capecitabine—kidney cancer	0.000435	0.00236	CcSEcCtD
Pralatrexate—Decreased appetite—Everolimus—kidney cancer	0.000434	0.00236	CcSEcCtD
Pralatrexate—Leukopenia—Dactinomycin—kidney cancer	0.000433	0.00235	CcSEcCtD
Pralatrexate—Diarrhoea—Pazopanib—kidney cancer	0.000433	0.00235	CcSEcCtD
Pralatrexate—Liver function test abnormal—Capecitabine—kidney cancer	0.000432	0.00235	CcSEcCtD
Pralatrexate—Fatigue—Everolimus—kidney cancer	0.00043	0.00234	CcSEcCtD
Pralatrexate—Dyspnoea—Erlotinib—kidney cancer	0.000429	0.00233	CcSEcCtD
Pralatrexate—Constipation—Vinblastine—kidney cancer	0.000428	0.00233	CcSEcCtD
Pralatrexate—Constipation—Everolimus—kidney cancer	0.000427	0.00232	CcSEcCtD
Pralatrexate—Vomiting—Temsirolimus—kidney cancer	0.000427	0.00232	CcSEcCtD
Pralatrexate—Hypokalaemia—Capecitabine—kidney cancer	0.000426	0.00231	CcSEcCtD
Pralatrexate—Thrombocytopenia—Sorafenib—kidney cancer	0.000424	0.00231	CcSEcCtD
Pralatrexate—Rash—Temsirolimus—kidney cancer	0.000423	0.0023	CcSEcCtD
Pralatrexate—Dermatitis—Temsirolimus—kidney cancer	0.000423	0.0023	CcSEcCtD
Pralatrexate—Toxic epidermal necrolysis—Capecitabine—kidney cancer	0.000421	0.00229	CcSEcCtD
Pralatrexate—Decreased appetite—Erlotinib—kidney cancer	0.000419	0.00228	CcSEcCtD
Pralatrexate—Back pain—Vincristine—kidney cancer	0.000418	0.00227	CcSEcCtD
Pralatrexate—Oedema—Sunitinib—kidney cancer	0.000417	0.00227	CcSEcCtD
Pralatrexate—Fatigue—Erlotinib—kidney cancer	0.000415	0.00226	CcSEcCtD
Pralatrexate—Epistaxis—Paclitaxel—kidney cancer	0.000414	0.00225	CcSEcCtD
Pralatrexate—Anorexia—Sorafenib—kidney cancer	0.000413	0.00225	CcSEcCtD
Pralatrexate—Constipation—Erlotinib—kidney cancer	0.000412	0.00224	CcSEcCtD
Pralatrexate—Gastrointestinal pain—Vinblastine—kidney cancer	0.00041	0.00223	CcSEcCtD
Pralatrexate—Thrombocytopenia—Sunitinib—kidney cancer	0.000408	0.00222	CcSEcCtD
Pralatrexate—Gastrointestinal pain—Everolimus—kidney cancer	0.000408	0.00222	CcSEcCtD
Pralatrexate—Vomiting—Pazopanib—kidney cancer	0.000402	0.00218	CcSEcCtD
Pralatrexate—Anaemia—Vincristine—kidney cancer	0.000399	0.00217	CcSEcCtD
Pralatrexate—Rash—Pazopanib—kidney cancer	0.000399	0.00217	CcSEcCtD
Pralatrexate—Nausea—Temsirolimus—kidney cancer	0.000399	0.00217	CcSEcCtD
Pralatrexate—Dermatitis—Pazopanib—kidney cancer	0.000398	0.00216	CcSEcCtD
Pralatrexate—Anorexia—Sunitinib—kidney cancer	0.000397	0.00216	CcSEcCtD
Pralatrexate—Back pain—Gemcitabine—kidney cancer	0.000396	0.00216	CcSEcCtD
Pralatrexate—Abdominal pain—Vinblastine—kidney cancer	0.000396	0.00215	CcSEcCtD
Pralatrexate—Oedema—Dactinomycin—kidney cancer	0.000395	0.00215	CcSEcCtD
Pralatrexate—Abdominal pain—Everolimus—kidney cancer	0.000395	0.00214	CcSEcCtD
Pralatrexate—Body temperature increased—Everolimus—kidney cancer	0.000395	0.00214	CcSEcCtD
Pralatrexate—Gastrointestinal pain—Erlotinib—kidney cancer	0.000394	0.00214	CcSEcCtD
Pralatrexate—Leukopenia—Vincristine—kidney cancer	0.000387	0.0021	CcSEcCtD
Pralatrexate—Thrombocytopenia—Dactinomycin—kidney cancer	0.000386	0.0021	CcSEcCtD
Pralatrexate—Dyspnoea—Sorafenib—kidney cancer	0.000386	0.0021	CcSEcCtD
Pralatrexate—Pancytopenia—Capecitabine—kidney cancer	0.000384	0.00209	CcSEcCtD
Pralatrexate—Abdominal pain—Erlotinib—kidney cancer	0.000381	0.00207	CcSEcCtD
Pralatrexate—Body temperature increased—Erlotinib—kidney cancer	0.000381	0.00207	CcSEcCtD
Pralatrexate—Anaemia—Gemcitabine—kidney cancer	0.000379	0.00206	CcSEcCtD
Pralatrexate—Neutropenia—Capecitabine—kidney cancer	0.000378	0.00205	CcSEcCtD
Pralatrexate—Decreased appetite—Sorafenib—kidney cancer	0.000377	0.00205	CcSEcCtD
Pralatrexate—Anorexia—Dactinomycin—kidney cancer	0.000376	0.00205	CcSEcCtD
Pralatrexate—Upper respiratory tract infection—Capecitabine—kidney cancer	0.000376	0.00204	CcSEcCtD
Pralatrexate—Nausea—Pazopanib—kidney cancer	0.000375	0.00204	CcSEcCtD
Pralatrexate—Fatigue—Sorafenib—kidney cancer	0.000374	0.00203	CcSEcCtD
Pralatrexate—Dyspnoea—Sunitinib—kidney cancer	0.000372	0.00202	CcSEcCtD
Pralatrexate—Constipation—Sorafenib—kidney cancer	0.000371	0.00201	CcSEcCtD
Pralatrexate—Leukopenia—Gemcitabine—kidney cancer	0.000367	0.00199	CcSEcCtD
Pralatrexate—Decreased appetite—Sunitinib—kidney cancer	0.000362	0.00197	CcSEcCtD
Pralatrexate—Sepsis—Doxorubicin—kidney cancer	0.00036	0.00196	CcSEcCtD
Pralatrexate—Asthenia—Vinblastine—kidney cancer	0.00036	0.00195	CcSEcCtD
Pralatrexate—Fatigue—Sunitinib—kidney cancer	0.000359	0.00195	CcSEcCtD
Pralatrexate—Asthenia—Everolimus—kidney cancer	0.000358	0.00195	CcSEcCtD
Pralatrexate—Cough—Gemcitabine—kidney cancer	0.000358	0.00194	CcSEcCtD
Pralatrexate—Constipation—Sunitinib—kidney cancer	0.000357	0.00194	CcSEcCtD
Pralatrexate—TYMS—Vinorelbine—Vincristine—kidney cancer	0.000356	0.0558	CbGdCrCtD
Pralatrexate—TYMS—Vinorelbine—Vinblastine—kidney cancer	0.000356	0.0558	CbGdCrCtD
Pralatrexate—Gastrointestinal pain—Sorafenib—kidney cancer	0.000354	0.00193	CcSEcCtD
Pralatrexate—Pruritus—Everolimus—kidney cancer	0.000353	0.00192	CcSEcCtD
Pralatrexate—Oedema—Vincristine—kidney cancer	0.000353	0.00192	CcSEcCtD
Pralatrexate—Asthenia—Erlotinib—kidney cancer	0.000346	0.00188	CcSEcCtD
Pralatrexate—Thrombocytopenia—Vincristine—kidney cancer	0.000345	0.00188	CcSEcCtD
Pralatrexate—Decreased appetite—Dactinomycin—kidney cancer	0.000343	0.00187	CcSEcCtD
Pralatrexate—Diarrhoea—Vinblastine—kidney cancer	0.000343	0.00186	CcSEcCtD
Pralatrexate—Abdominal pain—Sorafenib—kidney cancer	0.000343	0.00186	CcSEcCtD
Pralatrexate—Body temperature increased—Sorafenib—kidney cancer	0.000343	0.00186	CcSEcCtD
Pralatrexate—Diarrhoea—Everolimus—kidney cancer	0.000342	0.00186	CcSEcCtD
Pralatrexate—Gastrointestinal pain—Sunitinib—kidney cancer	0.000341	0.00185	CcSEcCtD
Pralatrexate—Pruritus—Erlotinib—kidney cancer	0.000341	0.00185	CcSEcCtD
Pralatrexate—Fatigue—Dactinomycin—kidney cancer	0.00034	0.00185	CcSEcCtD
Pralatrexate—Epistaxis—Capecitabine—kidney cancer	0.00034	0.00185	CcSEcCtD
Pralatrexate—Anorexia—Vincristine—kidney cancer	0.000336	0.00183	CcSEcCtD
Pralatrexate—Oedema—Gemcitabine—kidney cancer	0.000335	0.00182	CcSEcCtD
Pralatrexate—Back pain—Paclitaxel—kidney cancer	0.000332	0.0018	CcSEcCtD
Pralatrexate—Abdominal pain—Sunitinib—kidney cancer	0.00033	0.00179	CcSEcCtD
Pralatrexate—Body temperature increased—Sunitinib—kidney cancer	0.00033	0.00179	CcSEcCtD
Pralatrexate—Diarrhoea—Erlotinib—kidney cancer	0.00033	0.00179	CcSEcCtD
Pralatrexate—Thrombocytopenia—Gemcitabine—kidney cancer	0.000328	0.00178	CcSEcCtD
Pralatrexate—Gastrointestinal pain—Dactinomycin—kidney cancer	0.000323	0.00175	CcSEcCtD
Pralatrexate—Anorexia—Gemcitabine—kidney cancer	0.000319	0.00173	CcSEcCtD
Pralatrexate—Vomiting—Vinblastine—kidney cancer	0.000319	0.00173	CcSEcCtD
Pralatrexate—Vomiting—Everolimus—kidney cancer	0.000317	0.00173	CcSEcCtD
Pralatrexate—Anaemia—Paclitaxel—kidney cancer	0.000317	0.00172	CcSEcCtD
Pralatrexate—Rash—Everolimus—kidney cancer	0.000315	0.00171	CcSEcCtD
Pralatrexate—Dermatitis—Everolimus—kidney cancer	0.000314	0.00171	CcSEcCtD
Pralatrexate—Abdominal pain—Dactinomycin—kidney cancer	0.000312	0.0017	CcSEcCtD
Pralatrexate—Body temperature increased—Dactinomycin—kidney cancer	0.000312	0.0017	CcSEcCtD
Pralatrexate—Asthenia—Sorafenib—kidney cancer	0.000311	0.00169	CcSEcCtD
Pralatrexate—Leukopenia—Paclitaxel—kidney cancer	0.000307	0.00167	CcSEcCtD
Pralatrexate—Decreased appetite—Vincristine—kidney cancer	0.000307	0.00167	CcSEcCtD
Pralatrexate—Pruritus—Sorafenib—kidney cancer	0.000307	0.00167	CcSEcCtD
Pralatrexate—Vomiting—Erlotinib—kidney cancer	0.000306	0.00166	CcSEcCtD
Pralatrexate—TYMS—Vincristine—Vinblastine—kidney cancer	0.000304	0.0477	CbGdCrCtD
Pralatrexate—Fatigue—Vincristine—kidney cancer	0.000304	0.00165	CcSEcCtD
Pralatrexate—Rash—Erlotinib—kidney cancer	0.000304	0.00165	CcSEcCtD
Pralatrexate—Dermatitis—Erlotinib—kidney cancer	0.000303	0.00165	CcSEcCtD
Pralatrexate—Constipation—Vincristine—kidney cancer	0.000302	0.00164	CcSEcCtD
Pralatrexate—Pain in extremity—Doxorubicin—kidney cancer	0.000301	0.00164	CcSEcCtD
Pralatrexate—Cough—Paclitaxel—kidney cancer	0.000299	0.00163	CcSEcCtD
Pralatrexate—Asthenia—Sunitinib—kidney cancer	0.000299	0.00163	CcSEcCtD
Pralatrexate—Dyspnoea—Gemcitabine—kidney cancer	0.000298	0.00162	CcSEcCtD
Pralatrexate—Nausea—Vinblastine—kidney cancer	0.000298	0.00162	CcSEcCtD
Pralatrexate—Nausea—Everolimus—kidney cancer	0.000296	0.00161	CcSEcCtD
Pralatrexate—Diarrhoea—Sorafenib—kidney cancer	0.000296	0.00161	CcSEcCtD
Pralatrexate—Pruritus—Sunitinib—kidney cancer	0.000295	0.0016	CcSEcCtD
Pralatrexate—Decreased appetite—Gemcitabine—kidney cancer	0.000291	0.00158	CcSEcCtD
Pralatrexate—Fatigue—Gemcitabine—kidney cancer	0.000288	0.00157	CcSEcCtD
Pralatrexate—Gastrointestinal pain—Vincristine—kidney cancer	0.000288	0.00157	CcSEcCtD
Pralatrexate—Constipation—Gemcitabine—kidney cancer	0.000286	0.00156	CcSEcCtD
Pralatrexate—Nausea—Erlotinib—kidney cancer	0.000286	0.00156	CcSEcCtD
Pralatrexate—Diarrhoea—Sunitinib—kidney cancer	0.000285	0.00155	CcSEcCtD
Pralatrexate—Asthenia—Dactinomycin—kidney cancer	0.000283	0.00154	CcSEcCtD
Pralatrexate—Dehydration—Doxorubicin—kidney cancer	0.00028	0.00152	CcSEcCtD
Pralatrexate—Oedema—Paclitaxel—kidney cancer	0.00028	0.00152	CcSEcCtD
Pralatrexate—Abdominal pain—Vincristine—kidney cancer	0.000279	0.00152	CcSEcCtD
Pralatrexate—Body temperature increased—Vincristine—kidney cancer	0.000279	0.00152	CcSEcCtD
Pralatrexate—Liver function test abnormal—Doxorubicin—kidney cancer	0.000278	0.00151	CcSEcCtD
Pralatrexate—Vomiting—Sorafenib—kidney cancer	0.000275	0.0015	CcSEcCtD
Pralatrexate—Hypokalaemia—Doxorubicin—kidney cancer	0.000274	0.00149	CcSEcCtD
Pralatrexate—Thrombocytopenia—Paclitaxel—kidney cancer	0.000274	0.00149	CcSEcCtD
Pralatrexate—Tachycardia—Paclitaxel—kidney cancer	0.000273	0.00149	CcSEcCtD
Pralatrexate—Rash—Sorafenib—kidney cancer	0.000273	0.00149	CcSEcCtD
Pralatrexate—Dermatitis—Sorafenib—kidney cancer	0.000273	0.00148	CcSEcCtD
Pralatrexate—Back pain—Capecitabine—kidney cancer	0.000272	0.00148	CcSEcCtD
Pralatrexate—Toxic epidermal necrolysis—Doxorubicin—kidney cancer	0.000271	0.00148	CcSEcCtD
Pralatrexate—Diarrhoea—Dactinomycin—kidney cancer	0.00027	0.00147	CcSEcCtD
Pralatrexate—Anorexia—Paclitaxel—kidney cancer	0.000267	0.00145	CcSEcCtD
Pralatrexate—Vomiting—Sunitinib—kidney cancer	0.000265	0.00144	CcSEcCtD
Pralatrexate—Body temperature increased—Gemcitabine—kidney cancer	0.000264	0.00144	CcSEcCtD
Pralatrexate—Rash—Sunitinib—kidney cancer	0.000263	0.00143	CcSEcCtD
Pralatrexate—Dermatitis—Sunitinib—kidney cancer	0.000263	0.00143	CcSEcCtD
Pralatrexate—Anaemia—Capecitabine—kidney cancer	0.00026	0.00141	CcSEcCtD
Pralatrexate—Nausea—Sorafenib—kidney cancer	0.000257	0.0014	CcSEcCtD
Pralatrexate—Asthenia—Vincristine—kidney cancer	0.000253	0.00138	CcSEcCtD
Pralatrexate—Leukopenia—Capecitabine—kidney cancer	0.000252	0.00137	CcSEcCtD
Pralatrexate—Vomiting—Dactinomycin—kidney cancer	0.000251	0.00136	CcSEcCtD
Pralatrexate—Dyspnoea—Paclitaxel—kidney cancer	0.00025	0.00136	CcSEcCtD
Pralatrexate—Rash—Dactinomycin—kidney cancer	0.000249	0.00135	CcSEcCtD
Pralatrexate—Nausea—Sunitinib—kidney cancer	0.000248	0.00135	CcSEcCtD
Pralatrexate—Pancytopenia—Doxorubicin—kidney cancer	0.000247	0.00135	CcSEcCtD
Pralatrexate—Cough—Capecitabine—kidney cancer	0.000246	0.00134	CcSEcCtD
Pralatrexate—TYMS—Vinblastine—Vincristine—kidney cancer	0.000245	0.0384	CbGdCrCtD
Pralatrexate—Neutropenia—Doxorubicin—kidney cancer	0.000244	0.00132	CcSEcCtD
Pralatrexate—Decreased appetite—Paclitaxel—kidney cancer	0.000243	0.00132	CcSEcCtD
Pralatrexate—Upper respiratory tract infection—Doxorubicin—kidney cancer	0.000242	0.00132	CcSEcCtD
Pralatrexate—Fatigue—Paclitaxel—kidney cancer	0.000241	0.00131	CcSEcCtD
Pralatrexate—Diarrhoea—Vincristine—kidney cancer	0.000241	0.00131	CcSEcCtD
Pralatrexate—Asthenia—Gemcitabine—kidney cancer	0.00024	0.0013	CcSEcCtD
Pralatrexate—Constipation—Paclitaxel—kidney cancer	0.00024	0.0013	CcSEcCtD
Pralatrexate—Pruritus—Gemcitabine—kidney cancer	0.000237	0.00129	CcSEcCtD
Pralatrexate—Nausea—Dactinomycin—kidney cancer	0.000234	0.00127	CcSEcCtD
Pralatrexate—Oedema—Capecitabine—kidney cancer	0.00023	0.00125	CcSEcCtD
Pralatrexate—Gastrointestinal pain—Paclitaxel—kidney cancer	0.000229	0.00125	CcSEcCtD
Pralatrexate—Diarrhoea—Gemcitabine—kidney cancer	0.000229	0.00124	CcSEcCtD
Pralatrexate—Thrombocytopenia—Capecitabine—kidney cancer	0.000225	0.00122	CcSEcCtD
Pralatrexate—Tachycardia—Capecitabine—kidney cancer	0.000224	0.00122	CcSEcCtD
Pralatrexate—Vomiting—Vincristine—kidney cancer	0.000224	0.00122	CcSEcCtD
Pralatrexate—Rash—Vincristine—kidney cancer	0.000222	0.00121	CcSEcCtD
Pralatrexate—Dermatitis—Vincristine—kidney cancer	0.000222	0.00121	CcSEcCtD
Pralatrexate—Abdominal pain—Paclitaxel—kidney cancer	0.000221	0.0012	CcSEcCtD
Pralatrexate—Body temperature increased—Paclitaxel—kidney cancer	0.000221	0.0012	CcSEcCtD
Pralatrexate—Epistaxis—Doxorubicin—kidney cancer	0.000219	0.00119	CcSEcCtD
Pralatrexate—Anorexia—Capecitabine—kidney cancer	0.000219	0.00119	CcSEcCtD
Pralatrexate—Vomiting—Gemcitabine—kidney cancer	0.000213	0.00116	CcSEcCtD
Pralatrexate—Rash—Gemcitabine—kidney cancer	0.000211	0.00115	CcSEcCtD
Pralatrexate—Dermatitis—Gemcitabine—kidney cancer	0.000211	0.00115	CcSEcCtD
Pralatrexate—Nausea—Vincristine—kidney cancer	0.000209	0.00114	CcSEcCtD
Pralatrexate—Dyspnoea—Capecitabine—kidney cancer	0.000205	0.00111	CcSEcCtD
Pralatrexate—Asthenia—Paclitaxel—kidney cancer	0.000201	0.00109	CcSEcCtD
Pralatrexate—Decreased appetite—Capecitabine—kidney cancer	0.0002	0.00109	CcSEcCtD
Pralatrexate—Nausea—Gemcitabine—kidney cancer	0.000199	0.00108	CcSEcCtD
Pralatrexate—Fatigue—Capecitabine—kidney cancer	0.000198	0.00108	CcSEcCtD
Pralatrexate—Pruritus—Paclitaxel—kidney cancer	0.000198	0.00108	CcSEcCtD
Pralatrexate—Constipation—Capecitabine—kidney cancer	0.000197	0.00107	CcSEcCtD
Pralatrexate—Diarrhoea—Paclitaxel—kidney cancer	0.000192	0.00104	CcSEcCtD
Pralatrexate—Gastrointestinal pain—Capecitabine—kidney cancer	0.000188	0.00102	CcSEcCtD
Pralatrexate—Abdominal pain—Capecitabine—kidney cancer	0.000182	0.000988	CcSEcCtD
Pralatrexate—Body temperature increased—Capecitabine—kidney cancer	0.000182	0.000988	CcSEcCtD
Pralatrexate—Vomiting—Paclitaxel—kidney cancer	0.000178	0.000968	CcSEcCtD
Pralatrexate—Rash—Paclitaxel—kidney cancer	0.000177	0.00096	CcSEcCtD
Pralatrexate—Dermatitis—Paclitaxel—kidney cancer	0.000176	0.000959	CcSEcCtD
Pralatrexate—Back pain—Doxorubicin—kidney cancer	0.000176	0.000955	CcSEcCtD
Pralatrexate—Anaemia—Doxorubicin—kidney cancer	0.000168	0.000912	CcSEcCtD
Pralatrexate—DHFR—Folate Metabolism—TP53—kidney cancer	0.000166	0.00189	CbGpPWpGaD
Pralatrexate—Nausea—Paclitaxel—kidney cancer	0.000166	0.000904	CcSEcCtD
Pralatrexate—DHFR—Disease—AMER1—kidney cancer	0.000166	0.00189	CbGpPWpGaD
Pralatrexate—SLC19A1—Metabolism—SCARB1—kidney cancer	0.000165	0.00188	CbGpPWpGaD
Pralatrexate—Asthenia—Capecitabine—kidney cancer	0.000165	0.000896	CcSEcCtD
Pralatrexate—DHFR—Metabolism—PDHB—kidney cancer	0.000163	0.00186	CbGpPWpGaD
Pralatrexate—SLC19A1—Metabolism—PTGS1—kidney cancer	0.000163	0.00186	CbGpPWpGaD
Pralatrexate—TYMS—E2F transcription factor network—MYC—kidney cancer	0.000163	0.00186	CbGpPWpGaD
Pralatrexate—FPGS—Disease—PSMD7—kidney cancer	0.000163	0.00185	CbGpPWpGaD
Pralatrexate—Pruritus—Capecitabine—kidney cancer	0.000163	0.000884	CcSEcCtD
Pralatrexate—DHFR—Retinoblastoma (RB) in Cancer—MYC—kidney cancer	0.000163	0.00185	CbGpPWpGaD
Pralatrexate—FPGS—Metabolism—ITPR2—kidney cancer	0.000163	0.00185	CbGpPWpGaD
Pralatrexate—Leukopenia—Doxorubicin—kidney cancer	0.000162	0.000883	CcSEcCtD
Pralatrexate—SLC19A1—Metabolism—PSMD7—kidney cancer	0.00016	0.00182	CbGpPWpGaD
Pralatrexate—Cough—Doxorubicin—kidney cancer	0.000158	0.000861	CcSEcCtD
Pralatrexate—Diarrhoea—Capecitabine—kidney cancer	0.000157	0.000855	CcSEcCtD
Pralatrexate—TYMS—G1/S Transition—CDKN1B—kidney cancer	0.000155	0.00176	CbGpPWpGaD
Pralatrexate—DHFR—Metabolism—CCBL1—kidney cancer	0.000154	0.00175	CbGpPWpGaD
Pralatrexate—SLC19A1—Metabolism—BCHE—kidney cancer	0.000152	0.00173	CbGpPWpGaD
Pralatrexate—SLC19A1—Metabolism—SLC5A5—kidney cancer	0.00015	0.00171	CbGpPWpGaD
Pralatrexate—DHFR—Mitotic G1-G1/S phases—CDKN1B—kidney cancer	0.000149	0.0017	CbGpPWpGaD
Pralatrexate—FPGS—Metabolism—GSTT1—kidney cancer	0.000148	0.00169	CbGpPWpGaD
Pralatrexate—FPGS—Metabolism—ACHE—kidney cancer	0.000148	0.00169	CbGpPWpGaD
Pralatrexate—Oedema—Doxorubicin—kidney cancer	0.000148	0.000805	CcSEcCtD
Pralatrexate—DHFR—Cell Cycle, Mitotic—PSMD7—kidney cancer	0.000148	0.00168	CbGpPWpGaD
Pralatrexate—TYMS—Mitotic G1-G1/S phases—CDKN2A—kidney cancer	0.000147	0.00167	CbGpPWpGaD
Pralatrexate—FPGS—Disease—SLC2A1—kidney cancer	0.000147	0.00167	CbGpPWpGaD
Pralatrexate—Vomiting—Capecitabine—kidney cancer	0.000146	0.000794	CcSEcCtD
Pralatrexate—FPGS—Disease—JUNB—kidney cancer	0.000146	0.00166	CbGpPWpGaD
Pralatrexate—Thrombocytopenia—Doxorubicin—kidney cancer	0.000145	0.000789	CcSEcCtD
Pralatrexate—Rash—Capecitabine—kidney cancer	0.000145	0.000788	CcSEcCtD
Pralatrexate—SLC19A1—Metabolism—SLC2A1—kidney cancer	0.000145	0.00165	CbGpPWpGaD
Pralatrexate—Dermatitis—Capecitabine—kidney cancer	0.000145	0.000787	CcSEcCtD
Pralatrexate—Tachycardia—Doxorubicin—kidney cancer	0.000145	0.000786	CcSEcCtD
Pralatrexate—DHFR—Cell Cycle, Mitotic—AURKA—kidney cancer	0.000144	0.00164	CbGpPWpGaD
Pralatrexate—TYMS—Azacitidine—Gemcitabine—kidney cancer	0.000143	0.0225	CbGdCrCtD
Pralatrexate—TYMS—Metabolism—PDHB—kidney cancer	0.000143	0.00162	CbGpPWpGaD
Pralatrexate—DHFR—Mitotic G1-G1/S phases—CCND1—kidney cancer	0.000143	0.00162	CbGpPWpGaD
Pralatrexate—TYMS—Retinoblastoma (RB) in Cancer—MYC—kidney cancer	0.000142	0.00161	CbGpPWpGaD
Pralatrexate—Anorexia—Doxorubicin—kidney cancer	0.000141	0.000768	CcSEcCtD
Pralatrexate—FPGS—Metabolism—SCARB1—kidney cancer	0.00014	0.0016	CbGpPWpGaD
Pralatrexate—SLC19A1—Disease—CDKN2B—kidney cancer	0.00014	0.00159	CbGpPWpGaD
Pralatrexate—DHFR—Disease—GPC3—kidney cancer	0.000139	0.00158	CbGpPWpGaD
Pralatrexate—FPGS—Metabolism—PTGS1—kidney cancer	0.000139	0.00158	CbGpPWpGaD
Pralatrexate—TYMS—Integrated Pancreatic Cancer Pathway—APC—kidney cancer	0.000137	0.00156	CbGpPWpGaD
Pralatrexate—Nausea—Capecitabine—kidney cancer	0.000137	0.000742	CcSEcCtD
Pralatrexate—FPGS—Metabolism—PSMD7—kidney cancer	0.000136	0.00155	CbGpPWpGaD
Pralatrexate—DHFR—G1/S Transition—MYC—kidney cancer	0.000136	0.00154	CbGpPWpGaD
Pralatrexate—TYMS—Metabolism—CCBL1—kidney cancer	0.000134	0.00153	CbGpPWpGaD
Pralatrexate—DHFR—Retinoblastoma (RB) in Cancer—TP53—kidney cancer	0.000133	0.00152	CbGpPWpGaD
Pralatrexate—DHFR—Metabolism—PPAT—kidney cancer	0.000133	0.00152	CbGpPWpGaD
Pralatrexate—DHFR—Metabolism—GLIPR1—kidney cancer	0.000133	0.00152	CbGpPWpGaD
Pralatrexate—DHFR—Cell Cycle—PSMD7—kidney cancer	0.000132	0.00151	CbGpPWpGaD
Pralatrexate—Dyspnoea—Doxorubicin—kidney cancer	0.000132	0.000718	CcSEcCtD
Pralatrexate—TYMS—Mitotic G1-G1/S phases—CDKN1B—kidney cancer	0.00013	0.00148	CbGpPWpGaD
Pralatrexate—TYMS—Cell Cycle, Mitotic—PSMD7—kidney cancer	0.000129	0.00147	CbGpPWpGaD
Pralatrexate—FPGS—Metabolism—BCHE—kidney cancer	0.000129	0.00147	CbGpPWpGaD
Pralatrexate—DHFR—Cell Cycle—AURKA—kidney cancer	0.000129	0.00146	CbGpPWpGaD
Pralatrexate—Decreased appetite—Doxorubicin—kidney cancer	0.000129	0.0007	CcSEcCtD
Pralatrexate—DHFR—Disease—ST3GAL2—kidney cancer	0.000129	0.00146	CbGpPWpGaD
Pralatrexate—Fatigue—Doxorubicin—kidney cancer	0.000128	0.000694	CcSEcCtD
Pralatrexate—FPGS—Metabolism—SLC5A5—kidney cancer	0.000128	0.00145	CbGpPWpGaD
Pralatrexate—Constipation—Doxorubicin—kidney cancer	0.000127	0.000689	CcSEcCtD
Pralatrexate—TYMS—Cell Cycle, Mitotic—AURKA—kidney cancer	0.000126	0.00143	CbGpPWpGaD
Pralatrexate—TYMS—Mitotic G1-G1/S phases—CCND1—kidney cancer	0.000124	0.00141	CbGpPWpGaD
Pralatrexate—DHFR—Metabolism—APRT—kidney cancer	0.000124	0.00141	CbGpPWpGaD
Pralatrexate—DHFR—Metabolism—FH—kidney cancer	0.000124	0.00141	CbGpPWpGaD
Pralatrexate—FPGS—Metabolism—SLC2A1—kidney cancer	0.000123	0.0014	CbGpPWpGaD
Pralatrexate—Gastrointestinal pain—Doxorubicin—kidney cancer	0.000121	0.000659	CcSEcCtD
Pralatrexate—SLC19A1—Metabolism—GSTP1—kidney cancer	0.000121	0.00137	CbGpPWpGaD
Pralatrexate—DHFR—Disease—PGK1—kidney cancer	0.000121	0.00137	CbGpPWpGaD
Pralatrexate—DHFR—Disease—SLC5A3—kidney cancer	0.000121	0.00137	CbGpPWpGaD
Pralatrexate—FPGS—Disease—CDKN2B—kidney cancer	0.000119	0.00135	CbGpPWpGaD
Pralatrexate—TYMS—G1/S Transition—MYC—kidney cancer	0.000118	0.00135	CbGpPWpGaD
Pralatrexate—DHFR—Disease—LDHB—kidney cancer	0.000118	0.00135	CbGpPWpGaD
Pralatrexate—DHFR—Disease—SFRP2—kidney cancer	0.000118	0.00135	CbGpPWpGaD
Pralatrexate—Body temperature increased—Doxorubicin—kidney cancer	0.000117	0.000637	CcSEcCtD
Pralatrexate—Abdominal pain—Doxorubicin—kidney cancer	0.000117	0.000637	CcSEcCtD
Pralatrexate—DHFR—Metabolism—GPC3—kidney cancer	0.000116	0.00132	CbGpPWpGaD
Pralatrexate—TYMS—Retinoblastoma (RB) in Cancer—TP53—kidney cancer	0.000116	0.00132	CbGpPWpGaD
Pralatrexate—TYMS—Metabolism—GLIPR1—kidney cancer	0.000116	0.00132	CbGpPWpGaD
Pralatrexate—TYMS—Metabolism—PPAT—kidney cancer	0.000116	0.00132	CbGpPWpGaD
Pralatrexate—TYMS—Cell Cycle—PSMD7—kidney cancer	0.000116	0.00131	CbGpPWpGaD
Pralatrexate—SLC19A1—Metabolism—ABCB1—kidney cancer	0.000114	0.0013	CbGpPWpGaD
Pralatrexate—DHFR—Mitotic G1-G1/S phases—MYC—kidney cancer	0.000114	0.0013	CbGpPWpGaD
Pralatrexate—DHFR—Metabolism—CA2—kidney cancer	0.000113	0.00129	CbGpPWpGaD
Pralatrexate—TYMS—Cell Cycle—AURKA—kidney cancer	0.000112	0.00128	CbGpPWpGaD
Pralatrexate—SLC19A1—Disease—HIF1A—kidney cancer	0.000112	0.00127	CbGpPWpGaD
Pralatrexate—SLC19A1—Disease—TSC2—kidney cancer	0.000111	0.00127	CbGpPWpGaD
Pralatrexate—SLC19A1—Metabolism—GSTM1—kidney cancer	0.000111	0.00126	CbGpPWpGaD
Pralatrexate—DHFR—Metabolism—ALAD—kidney cancer	0.00011	0.00126	CbGpPWpGaD
Pralatrexate—DHFR—Disease—TCEB2—kidney cancer	0.00011	0.00125	CbGpPWpGaD
Pralatrexate—DHFR—Disease—TCEB1—kidney cancer	0.00011	0.00125	CbGpPWpGaD
Pralatrexate—DHFR—Cell Cycle, Mitotic—CDKN2B—kidney cancer	0.000108	0.00123	CbGpPWpGaD
Pralatrexate—TYMS—Metabolism—FH—kidney cancer	0.000108	0.00123	CbGpPWpGaD
Pralatrexate—TYMS—Metabolism—APRT—kidney cancer	0.000108	0.00123	CbGpPWpGaD
Pralatrexate—TYMS—Integrated Pancreatic Cancer Pathway—RAF1—kidney cancer	0.000108	0.00123	CbGpPWpGaD
Pralatrexate—DHFR—Metabolism—ST3GAL2—kidney cancer	0.000108	0.00123	CbGpPWpGaD
Pralatrexate—TYMS—Integrated Pancreatic Cancer Pathway—ERBB2—kidney cancer	0.000107	0.00121	CbGpPWpGaD
Pralatrexate—Asthenia—Doxorubicin—kidney cancer	0.000106	0.000578	CcSEcCtD
Pralatrexate—DHFR—Metabolism—ALDH1A1—kidney cancer	0.000105	0.0012	CbGpPWpGaD
Pralatrexate—SLC19A1—Metabolism—CYP1A1—kidney cancer	0.000105	0.0012	CbGpPWpGaD
Pralatrexate—Pruritus—Doxorubicin—kidney cancer	0.000105	0.00057	CcSEcCtD
Pralatrexate—TYMS—Integrated Pancreatic Cancer Pathway—PTGS2—kidney cancer	0.000104	0.00119	CbGpPWpGaD
Pralatrexate—FPGS—Metabolism—GSTP1—kidney cancer	0.000103	0.00117	CbGpPWpGaD
Pralatrexate—TYMS—Metabolism—GPC3—kidney cancer	0.000102	0.00116	CbGpPWpGaD
Pralatrexate—Diarrhoea—Doxorubicin—kidney cancer	0.000101	0.000551	CcSEcCtD
Pralatrexate—DHFR—Metabolism—SLC5A3—kidney cancer	0.000101	0.00115	CbGpPWpGaD
Pralatrexate—DHFR—Metabolism—PGK1—kidney cancer	0.000101	0.00115	CbGpPWpGaD
Pralatrexate—TYMS—Mitotic G1-G1/S phases—MYC—kidney cancer	9.98e-05	0.00113	CbGpPWpGaD
Pralatrexate—DHFR—Metabolism—LDHB—kidney cancer	9.91e-05	0.00113	CbGpPWpGaD
Pralatrexate—TYMS—Metabolism—CA2—kidney cancer	9.89e-05	0.00112	CbGpPWpGaD
Pralatrexate—TYMS—Integrated Pancreatic Cancer Pathway—CDKN1B—kidney cancer	9.88e-05	0.00112	CbGpPWpGaD
Pralatrexate—SLC19A1—Disease—KIT—kidney cancer	9.84e-05	0.00112	CbGpPWpGaD
Pralatrexate—SLC19A1—Disease—APC—kidney cancer	9.84e-05	0.00112	CbGpPWpGaD
Pralatrexate—DHFR—Cell Cycle—BRCA2—kidney cancer	9.76e-05	0.00111	CbGpPWpGaD
Pralatrexate—FPGS—Metabolism—ABCB1—kidney cancer	9.72e-05	0.00111	CbGpPWpGaD
Pralatrexate—DHFR—Cell Cycle—CDKN2B—kidney cancer	9.68e-05	0.0011	CbGpPWpGaD
Pralatrexate—TYMS—Metabolism—ALAD—kidney cancer	9.64e-05	0.0011	CbGpPWpGaD
Pralatrexate—FPGS—Disease—HIF1A—kidney cancer	9.5e-05	0.00108	CbGpPWpGaD
Pralatrexate—FPGS—Disease—TSC2—kidney cancer	9.48e-05	0.00108	CbGpPWpGaD
Pralatrexate—TYMS—Cell Cycle, Mitotic—CDKN2B—kidney cancer	9.44e-05	0.00107	CbGpPWpGaD
Pralatrexate—FPGS—Metabolism—GSTM1—kidney cancer	9.44e-05	0.00107	CbGpPWpGaD
Pralatrexate—TYMS—Integrated Pancreatic Cancer Pathway—CCND1—kidney cancer	9.43e-05	0.00107	CbGpPWpGaD
Pralatrexate—Vomiting—Doxorubicin—kidney cancer	9.42e-05	0.000512	CcSEcCtD
Pralatrexate—TYMS—Metabolism—ST3GAL2—kidney cancer	9.41e-05	0.00107	CbGpPWpGaD
Pralatrexate—TYMS—Integrated Pancreatic Cancer Pathway—JUN—kidney cancer	9.41e-05	0.00107	CbGpPWpGaD
Pralatrexate—Rash—Doxorubicin—kidney cancer	9.34e-05	0.000508	CcSEcCtD
Pralatrexate—DHFR—Cell Cycle, Mitotic—BIRC5—kidney cancer	9.34e-05	0.00106	CbGpPWpGaD
Pralatrexate—TYMS—Integrated Pancreatic Cancer Pathway—CTNNB1—kidney cancer	9.33e-05	0.00106	CbGpPWpGaD
Pralatrexate—Dermatitis—Doxorubicin—kidney cancer	9.33e-05	0.000507	CcSEcCtD
Pralatrexate—SLC19A1—Disease—BRAF—kidney cancer	9.25e-05	0.00105	CbGpPWpGaD
Pralatrexate—TYMS—Metabolism—ALDH1A1—kidney cancer	9.19e-05	0.00105	CbGpPWpGaD
Pralatrexate—TYMS—Integrated Pancreatic Cancer Pathway—PTEN—kidney cancer	9.1e-05	0.00103	CbGpPWpGaD
Pralatrexate—TYMS—Circadian rythm related genes—JUN—kidney cancer	9.03e-05	0.00103	CbGpPWpGaD
Pralatrexate—DHFR—Disease—RPL14—kidney cancer	8.96e-05	0.00102	CbGpPWpGaD
Pralatrexate—FPGS—Metabolism—CYP1A1—kidney cancer	8.95e-05	0.00102	CbGpPWpGaD
Pralatrexate—TYMS—Metabolism—PGK1—kidney cancer	8.81e-05	0.001	CbGpPWpGaD
Pralatrexate—TYMS—Metabolism—SLC5A3—kidney cancer	8.81e-05	0.001	CbGpPWpGaD
Pralatrexate—Nausea—Doxorubicin—kidney cancer	8.8e-05	0.000478	CcSEcCtD
Pralatrexate—TYMS—Circadian rythm related genes—PTEN—kidney cancer	8.73e-05	0.000993	CbGpPWpGaD
Pralatrexate—TYMS—Metabolism—LDHB—kidney cancer	8.64e-05	0.000983	CbGpPWpGaD
Pralatrexate—DHFR—Metabolism—CA9—kidney cancer	8.59e-05	0.000977	CbGpPWpGaD
Pralatrexate—TYMS—Cell Cycle—BRCA2—kidney cancer	8.52e-05	0.000969	CbGpPWpGaD
Pralatrexate—TYMS—Cell Cycle—CDKN2B—kidney cancer	8.44e-05	0.00096	CbGpPWpGaD
Pralatrexate—FPGS—Disease—KIT—kidney cancer	8.37e-05	0.000952	CbGpPWpGaD
Pralatrexate—FPGS—Disease—APC—kidney cancer	8.37e-05	0.000952	CbGpPWpGaD
Pralatrexate—DHFR—Cell Cycle—BIRC5—kidney cancer	8.35e-05	0.00095	CbGpPWpGaD
Pralatrexate—TYMS—Integrated Pancreatic Cancer Pathway—VEGFA—kidney cancer	8.22e-05	0.000934	CbGpPWpGaD
Pralatrexate—TYMS—Cell Cycle, Mitotic—BIRC5—kidney cancer	8.15e-05	0.000927	CbGpPWpGaD
Pralatrexate—DHFR—Disease—ITPR2—kidney cancer	8.11e-05	0.000922	CbGpPWpGaD
Pralatrexate—FPGS—Disease—BRAF—kidney cancer	7.87e-05	0.000895	CbGpPWpGaD
Pralatrexate—SLC19A1—Metabolism—POMC—kidney cancer	7.85e-05	0.000892	CbGpPWpGaD
Pralatrexate—TYMS—Integrated Pancreatic Cancer Pathway—MAPK3—kidney cancer	7.77e-05	0.000884	CbGpPWpGaD
Pralatrexate—SLC19A1—Disease—RAF1—kidney cancer	7.73e-05	0.000879	CbGpPWpGaD
Pralatrexate—SLC19A1—Disease—ERBB2—kidney cancer	7.64e-05	0.000869	CbGpPWpGaD
Pralatrexate—TYMS—Integrated Pancreatic Cancer Pathway—MYC—kidney cancer	7.56e-05	0.00086	CbGpPWpGaD
Pralatrexate—SLC19A1—Disease—MTOR—kidney cancer	7.54e-05	0.000858	CbGpPWpGaD
Pralatrexate—SLC19A1—Disease—CD4—kidney cancer	7.53e-05	0.000856	CbGpPWpGaD
Pralatrexate—TYMS—Metabolism—CA9—kidney cancer	7.49e-05	0.000852	CbGpPWpGaD
Pralatrexate—SLC19A1—Disease—PTGS2—kidney cancer	7.47e-05	0.00085	CbGpPWpGaD
Pralatrexate—TYMS—Integrated Pancreatic Cancer Pathway—MAPK1—kidney cancer	7.4e-05	0.000841	CbGpPWpGaD
Pralatrexate—DHFR—Metabolism—CRABP1—kidney cancer	7.3e-05	0.00083	CbGpPWpGaD
Pralatrexate—TYMS—Cell Cycle—BIRC5—kidney cancer	7.29e-05	0.000829	CbGpPWpGaD
Pralatrexate—SLC19A1—Disease—CDKN1B—kidney cancer	7.08e-05	0.000805	CbGpPWpGaD
Pralatrexate—TYMS—Integrated Pancreatic Cancer Pathway—KRAS—kidney cancer	6.99e-05	0.000794	CbGpPWpGaD
Pralatrexate—DHFR—Disease—PSMD7—kidney cancer	6.79e-05	0.000773	CbGpPWpGaD
Pralatrexate—DHFR—Metabolism—ITPR2—kidney cancer	6.79e-05	0.000772	CbGpPWpGaD
Pralatrexate—SLC19A1—Disease—CTNNB1—kidney cancer	6.69e-05	0.00076	CbGpPWpGaD
Pralatrexate—FPGS—Metabolism—POMC—kidney cancer	6.67e-05	0.000759	CbGpPWpGaD
Pralatrexate—FPGS—Disease—RAF1—kidney cancer	6.57e-05	0.000747	CbGpPWpGaD
Pralatrexate—SLC19A1—Disease—PTEN—kidney cancer	6.52e-05	0.000741	CbGpPWpGaD
Pralatrexate—FPGS—Disease—ERBB2—kidney cancer	6.5e-05	0.000739	CbGpPWpGaD
Pralatrexate—TYMS—Integrated Pancreatic Cancer Pathway—PIK3CA—kidney cancer	6.42e-05	0.00073	CbGpPWpGaD
Pralatrexate—FPGS—Disease—MTOR—kidney cancer	6.41e-05	0.000729	CbGpPWpGaD
Pralatrexate—FPGS—Disease—CD4—kidney cancer	6.4e-05	0.000728	CbGpPWpGaD
Pralatrexate—TYMS—Metabolism—CRABP1—kidney cancer	6.37e-05	0.000725	CbGpPWpGaD
Pralatrexate—FPGS—Disease—PTGS2—kidney cancer	6.35e-05	0.000723	CbGpPWpGaD
Pralatrexate—SLC19A1—Metabolism—PTGS2—kidney cancer	6.26e-05	0.000712	CbGpPWpGaD
Pralatrexate—TYMS—Integrated Pancreatic Cancer Pathway—TP53—kidney cancer	6.21e-05	0.000706	CbGpPWpGaD
Pralatrexate—DHFR—Metabolism—GSTT1—kidney cancer	6.19e-05	0.000704	CbGpPWpGaD
Pralatrexate—DHFR—Metabolism—ACHE—kidney cancer	6.19e-05	0.000704	CbGpPWpGaD
Pralatrexate—DHFR—Cell Cycle, Mitotic—CDKN2A—kidney cancer	6.19e-05	0.000704	CbGpPWpGaD
Pralatrexate—DHFR—Disease—SLC2A1—kidney cancer	6.14e-05	0.000699	CbGpPWpGaD
Pralatrexate—DHFR—Disease—JUNB—kidney cancer	6.1e-05	0.000694	CbGpPWpGaD
Pralatrexate—FPGS—Disease—CDKN1B—kidney cancer	6.02e-05	0.000684	CbGpPWpGaD
Pralatrexate—TYMS—Circadian rythm related genes—TP53—kidney cancer	5.96e-05	0.000678	CbGpPWpGaD
Pralatrexate—TYMS—Metabolism—ITPR2—kidney cancer	5.92e-05	0.000674	CbGpPWpGaD
Pralatrexate—DHFR—Metabolism—SCARB1—kidney cancer	5.86e-05	0.000666	CbGpPWpGaD
Pralatrexate—DHFR—Metabolism—PTGS1—kidney cancer	5.8e-05	0.00066	CbGpPWpGaD
Pralatrexate—DHFR—Metabolism—PSMD7—kidney cancer	5.69e-05	0.000647	CbGpPWpGaD
Pralatrexate—FPGS—Disease—CTNNB1—kidney cancer	5.69e-05	0.000647	CbGpPWpGaD
Pralatrexate—SLC19A1—Disease—MAPK3—kidney cancer	5.57e-05	0.000633	CbGpPWpGaD
Pralatrexate—FPGS—Disease—PTEN—kidney cancer	5.54e-05	0.00063	CbGpPWpGaD
Pralatrexate—DHFR—Cell Cycle—CDKN2A—kidney cancer	5.53e-05	0.000629	CbGpPWpGaD
Pralatrexate—DHFR—Cell Cycle, Mitotic—CDKN1B—kidney cancer	5.48e-05	0.000623	CbGpPWpGaD
Pralatrexate—SLC19A1—Metabolism—PTEN—kidney cancer	5.46e-05	0.000621	CbGpPWpGaD
Pralatrexate—SLC19A1—Disease—MYC—kidney cancer	5.42e-05	0.000616	CbGpPWpGaD
Pralatrexate—TYMS—Metabolism—ACHE—kidney cancer	5.4e-05	0.000614	CbGpPWpGaD
Pralatrexate—TYMS—Metabolism—GSTT1—kidney cancer	5.4e-05	0.000614	CbGpPWpGaD
Pralatrexate—TYMS—Cell Cycle, Mitotic—CDKN2A—kidney cancer	5.4e-05	0.000614	CbGpPWpGaD
Pralatrexate—DHFR—Metabolism—BCHE—kidney cancer	5.39e-05	0.000613	CbGpPWpGaD
Pralatrexate—DHFR—Metabolism—SLC5A5—kidney cancer	5.33e-05	0.000606	CbGpPWpGaD
Pralatrexate—FPGS—Metabolism—PTGS2—kidney cancer	5.32e-05	0.000605	CbGpPWpGaD
Pralatrexate—SLC19A1—Disease—MAPK1—kidney cancer	5.3e-05	0.000603	CbGpPWpGaD
Pralatrexate—DHFR—Cell Cycle, Mitotic—CCND1—kidney cancer	5.23e-05	0.000595	CbGpPWpGaD
Pralatrexate—DHFR—Metabolism—SLC2A1—kidney cancer	5.15e-05	0.000585	CbGpPWpGaD
Pralatrexate—TYMS—Metabolism—SCARB1—kidney cancer	5.11e-05	0.000582	CbGpPWpGaD
Pralatrexate—TYMS—Metabolism—PTGS1—kidney cancer	5.06e-05	0.000576	CbGpPWpGaD
Pralatrexate—SLC19A1—Disease—KRAS—kidney cancer	5.01e-05	0.000569	CbGpPWpGaD
Pralatrexate—DHFR—Disease—CDKN2B—kidney cancer	4.96e-05	0.000565	CbGpPWpGaD
Pralatrexate—TYMS—Metabolism—PSMD7—kidney cancer	4.96e-05	0.000565	CbGpPWpGaD
Pralatrexate—DHFR—Cell Cycle—CDKN1B—kidney cancer	4.9e-05	0.000557	CbGpPWpGaD
Pralatrexate—TYMS—Cell Cycle—CDKN2A—kidney cancer	4.83e-05	0.000549	CbGpPWpGaD
Pralatrexate—TYMS—Cell Cycle, Mitotic—CDKN1B—kidney cancer	4.78e-05	0.000544	CbGpPWpGaD
Pralatrexate—FPGS—Disease—MAPK3—kidney cancer	4.74e-05	0.000538	CbGpPWpGaD
Pralatrexate—TYMS—Metabolism—BCHE—kidney cancer	4.71e-05	0.000535	CbGpPWpGaD
Pralatrexate—DHFR—Cell Cycle—CCND1—kidney cancer	4.68e-05	0.000532	CbGpPWpGaD
Pralatrexate—TYMS—Metabolism—SLC5A5—kidney cancer	4.65e-05	0.000529	CbGpPWpGaD
Pralatrexate—FPGS—Metabolism—PTEN—kidney cancer	4.64e-05	0.000528	CbGpPWpGaD
Pralatrexate—FPGS—Disease—MYC—kidney cancer	4.61e-05	0.000524	CbGpPWpGaD
Pralatrexate—SLC19A1—Disease—PIK3CA—kidney cancer	4.6e-05	0.000523	CbGpPWpGaD
Pralatrexate—TYMS—Cell Cycle, Mitotic—CCND1—kidney cancer	4.56e-05	0.000519	CbGpPWpGaD
Pralatrexate—FPGS—Disease—MAPK1—kidney cancer	4.51e-05	0.000512	CbGpPWpGaD
Pralatrexate—TYMS—Metabolism—SLC2A1—kidney cancer	4.49e-05	0.000511	CbGpPWpGaD
Pralatrexate—DHFR—Cell Cycle, Mitotic—MAPK3—kidney cancer	4.31e-05	0.00049	CbGpPWpGaD
Pralatrexate—DHFR—Metabolism—GSTP1—kidney cancer	4.29e-05	0.000488	CbGpPWpGaD
Pralatrexate—TYMS—Cell Cycle—CDKN1B—kidney cancer	4.28e-05	0.000486	CbGpPWpGaD
Pralatrexate—FPGS—Disease—KRAS—kidney cancer	4.26e-05	0.000484	CbGpPWpGaD
Pralatrexate—DHFR—Cell Cycle, Mitotic—MYC—kidney cancer	4.19e-05	0.000477	CbGpPWpGaD
Pralatrexate—DHFR—Cell Cycle, Mitotic—MAPK1—kidney cancer	4.1e-05	0.000467	CbGpPWpGaD
Pralatrexate—TYMS—Cell Cycle—CCND1—kidney cancer	4.08e-05	0.000464	CbGpPWpGaD
Pralatrexate—DHFR—Metabolism—ABCB1—kidney cancer	4.06e-05	0.000462	CbGpPWpGaD
Pralatrexate—DHFR—Disease—HIF1A—kidney cancer	3.97e-05	0.000451	CbGpPWpGaD
Pralatrexate—DHFR—Disease—TSC2—kidney cancer	3.96e-05	0.00045	CbGpPWpGaD
Pralatrexate—DHFR—Metabolism—GSTM1—kidney cancer	3.94e-05	0.000448	CbGpPWpGaD
Pralatrexate—FPGS—Disease—PIK3CA—kidney cancer	3.91e-05	0.000445	CbGpPWpGaD
Pralatrexate—DHFR—Cell Cycle—MAPK3—kidney cancer	3.86e-05	0.000438	CbGpPWpGaD
Pralatrexate—SLC19A1—Metabolism—PIK3CA—kidney cancer	3.85e-05	0.000438	CbGpPWpGaD
Pralatrexate—TYMS—Cell Cycle, Mitotic—MAPK3—kidney cancer	3.76e-05	0.000428	CbGpPWpGaD
Pralatrexate—DHFR—Cell Cycle—MYC—kidney cancer	3.75e-05	0.000426	CbGpPWpGaD
Pralatrexate—TYMS—Metabolism—GSTP1—kidney cancer	3.74e-05	0.000426	CbGpPWpGaD
Pralatrexate—DHFR—Metabolism—CYP1A1—kidney cancer	3.74e-05	0.000425	CbGpPWpGaD
Pralatrexate—DHFR—Cell Cycle—MAPK1—kidney cancer	3.67e-05	0.000417	CbGpPWpGaD
Pralatrexate—TYMS—Cell Cycle, Mitotic—MYC—kidney cancer	3.66e-05	0.000416	CbGpPWpGaD
Pralatrexate—TYMS—Cell Cycle, Mitotic—MAPK1—kidney cancer	3.58e-05	0.000407	CbGpPWpGaD
Pralatrexate—TYMS—Metabolism—ABCB1—kidney cancer	3.54e-05	0.000403	CbGpPWpGaD
Pralatrexate—DHFR—Disease—APC—kidney cancer	3.5e-05	0.000398	CbGpPWpGaD
Pralatrexate—DHFR—Disease—KIT—kidney cancer	3.5e-05	0.000398	CbGpPWpGaD
Pralatrexate—TYMS—Metabolism—GSTM1—kidney cancer	3.44e-05	0.000391	CbGpPWpGaD
Pralatrexate—TYMS—Cell Cycle—MAPK3—kidney cancer	3.36e-05	0.000383	CbGpPWpGaD
Pralatrexate—DHFR—Disease—BRAF—kidney cancer	3.29e-05	0.000374	CbGpPWpGaD
Pralatrexate—FPGS—Metabolism—PIK3CA—kidney cancer	3.27e-05	0.000372	CbGpPWpGaD
Pralatrexate—TYMS—Cell Cycle—MYC—kidney cancer	3.27e-05	0.000372	CbGpPWpGaD
Pralatrexate—TYMS—Metabolism—CYP1A1—kidney cancer	3.26e-05	0.000371	CbGpPWpGaD
Pralatrexate—TYMS—Cell Cycle—MAPK1—kidney cancer	3.2e-05	0.000364	CbGpPWpGaD
Pralatrexate—DHFR—Cell Cycle—TP53—kidney cancer	3.08e-05	0.00035	CbGpPWpGaD
Pralatrexate—DHFR—Metabolism—POMC—kidney cancer	2.79e-05	0.000317	CbGpPWpGaD
Pralatrexate—DHFR—Disease—RAF1—kidney cancer	2.74e-05	0.000312	CbGpPWpGaD
Pralatrexate—DHFR—Disease—ERBB2—kidney cancer	2.71e-05	0.000309	CbGpPWpGaD
Pralatrexate—TYMS—Cell Cycle—TP53—kidney cancer	2.69e-05	0.000306	CbGpPWpGaD
Pralatrexate—DHFR—Disease—MTOR—kidney cancer	2.68e-05	0.000305	CbGpPWpGaD
Pralatrexate—DHFR—Disease—CD4—kidney cancer	2.67e-05	0.000304	CbGpPWpGaD
Pralatrexate—DHFR—Disease—PTGS2—kidney cancer	2.65e-05	0.000302	CbGpPWpGaD
Pralatrexate—DHFR—Disease—CDKN1B—kidney cancer	2.51e-05	0.000286	CbGpPWpGaD
Pralatrexate—TYMS—Metabolism—POMC—kidney cancer	2.43e-05	0.000277	CbGpPWpGaD
Pralatrexate—DHFR—Disease—CTNNB1—kidney cancer	2.38e-05	0.00027	CbGpPWpGaD
Pralatrexate—DHFR—Disease—PTEN—kidney cancer	2.32e-05	0.000263	CbGpPWpGaD
Pralatrexate—DHFR—Metabolism—PTGS2—kidney cancer	2.22e-05	0.000253	CbGpPWpGaD
Pralatrexate—DHFR—Disease—MAPK3—kidney cancer	1.98e-05	0.000225	CbGpPWpGaD
Pralatrexate—TYMS—Metabolism—PTGS2—kidney cancer	1.94e-05	0.000221	CbGpPWpGaD
Pralatrexate—DHFR—Metabolism—PTEN—kidney cancer	1.94e-05	0.00022	CbGpPWpGaD
Pralatrexate—DHFR—Disease—MYC—kidney cancer	1.92e-05	0.000219	CbGpPWpGaD
Pralatrexate—DHFR—Disease—MAPK1—kidney cancer	1.88e-05	0.000214	CbGpPWpGaD
Pralatrexate—DHFR—Disease—KRAS—kidney cancer	1.78e-05	0.000202	CbGpPWpGaD
Pralatrexate—TYMS—Metabolism—PTEN—kidney cancer	1.69e-05	0.000192	CbGpPWpGaD
Pralatrexate—DHFR—Disease—PIK3CA—kidney cancer	1.63e-05	0.000186	CbGpPWpGaD
Pralatrexate—DHFR—Metabolism—PIK3CA—kidney cancer	1.37e-05	0.000156	CbGpPWpGaD
Pralatrexate—TYMS—Metabolism—PIK3CA—kidney cancer	1.19e-05	0.000136	CbGpPWpGaD
